{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:07:23Z","timestamp":1789589243932,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T00:00:00Z","timestamp":1531440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11523-018-0579-9","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T11:05:43Z","timestamp":1531479943000},"page":"509-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6311-0256","authenticated-orcid":false,"given":"Marion","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Carmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pageot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Bejan-Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Vermes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Marchand-Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,13]]},"reference":[{"key":"579_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","volume":"11","author":"T-YD Cheng","year":"2016","unstructured":"Cheng T-YD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016;11:1653\u201371. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2016.05.021\n                    \n                  .","journal-title":"J Thorac Oncol"},{"key":"579_CR2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.18632\/oncotarget.1760","volume":"5","author":"S Kawabata","year":"2014","unstructured":"Kawabata S, Chiang C-T, Tsurutani J, et al. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. Oncotarget. 2014;5:1062\u201370. \n                    https:\/\/doi.org\/10.18632\/oncotarget.1760\n                    \n                  .","journal-title":"Oncotarget"},{"key":"579_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/annonc\/mdr564","volume":"23","author":"L Decoster","year":"2012","unstructured":"Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol. 2012;23:1387\u201393. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdr564\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"579_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342. \n                    https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00923.x\n                    \n                  .","journal-title":"Immunol Rev"},{"key":"579_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","volume":"2","author":"AH Sharpe","year":"2002","unstructured":"Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116\u201326. \n                    https:\/\/doi.org\/10.1038\/nri727\n                    \n                  .","journal-title":"Nat Rev Immunol"},{"key":"579_CR6","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","volume":"29","author":"SL Topalian","year":"2011","unstructured":"Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29:4828\u201336. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.38.0899\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"579_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504627\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"579_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1507643\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"579_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7\n                    \n                  .","journal-title":"Lancet"},{"key":"579_CR10","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","volume":"27","author":"S Novello","year":"2016","unstructured":"Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v1\u201327. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw326\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"579_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X\n                    \n                  .","journal-title":"Lancet"},{"key":"579_CR12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1200690\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"579_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJMc1505197","volume":"373","author":"M Nishino","year":"2015","unstructured":"Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373:288\u201390. \n                    https:\/\/doi.org\/10.1056\/NEJMc1505197\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"key":"579_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1606774\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"579_CR16","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837\u201346. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)00587-0\n                    \n                  .","journal-title":"Lancet"},{"key":"579_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"579_CR18","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/annonc\/mdx326","volume":"28","author":"Y Tomita","year":"2017","unstructured":"Tomita Y, Sueta D, Kakiuchi Y, et al. Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. Ann Oncol. 2017;28:2893\u20135. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx326\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"579_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210\u201325. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.02.024\n                    \n                  .","journal-title":"Eur J Cancer"},{"key":"579_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50. \n                    https:\/\/doi.org\/10.1186\/s40425-016-0152-y\n                    \n                  .","journal-title":"J Immunother Cancer"},{"key":"579_CR21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1051\/medsci\/20132912006.","volume":"29","author":"M Larsen","year":"2013","unstructured":"Larsen M, Appay V, Sauce D. Influence of PD-1 on the immunological synapse: a facet of immune regulation\u00a0? Med Sci. 2013;29:1080\u20132. \n                    https:\/\/doi.org\/10.1051\/medsci\/20132912006.","journal-title":"Med Sci"},{"key":"579_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319\u201322. \n                    https:\/\/doi.org\/10.1126\/science.291.5502.319\n                    \n                  .","journal-title":"Science"},{"key":"579_CR23","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, Grabie N, Bu D, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell mediated myocarditis. J Immunol. 2012;188:4876\u201384. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1200389\n                    \n                  .","journal-title":"J Immunol"},{"key":"579_CR24","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477\u201383. \n                    https:\/\/doi.org\/10.1038\/nm955\n                    \n                  .","journal-title":"Nat Med"},{"key":"579_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jcph.818","volume":"57","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Statkevich P, Bajaj G, et al. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Pharmacol. 2017;57:394\u2013400. \n                    https:\/\/doi.org\/10.1002\/jcph.818\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"key":"579_CR26","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jaip.2017.01.015","volume":"5","author":"M S\u00e1enz de Santa Mar\u00eda Garc\u00eda","year":"2017","unstructured":"S\u00e1enz de Santa Mar\u00eda Garc\u00eda M, Noguerado-Mellado B, Rojas-P\u00e9rez-Ezquerra P, Prieto-Garc\u00eda A, Bartolom\u00e9-Zavala B, Tornero P. First case of allergy to nivolumab. J Allergy Clin Immunol Pract. 2017;5:1140\u20131. \n                    https:\/\/doi.org\/10.1016\/j.jaip.2017.01.015\n                    \n                  .","journal-title":"J Allergy Clin Immunol Pract"},{"key":"579_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1172\/JCI118476","volume":"97","author":"H Shimokawa","year":"1996","unstructured":"Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest. 1996;97:769\u201376. \n                    https:\/\/doi.org\/10.1172\/JCI118476\n                    \n                  .","journal-title":"J Clin Invest"},{"key":"579_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/0735-1097(94)90419-7","volume":"23","author":"M Yamagishi","year":"1994","unstructured":"Yamagishi M, Miyatake K, Tamai J, Nakatani S, Koyama J, Nissen SE. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. J Am Coll Cardiol. 1994;23:352\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"579_CR29","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1111\/bph.13802","volume":"174","author":"AC Foks","year":"2017","unstructured":"Foks AC, Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br J Pharmacol. 2017;174:3940\u201355. \n                    https:\/\/doi.org\/10.1111\/bph.13802\n                    \n                  .","journal-title":"Br J Pharmacol"},{"key":"579_CR30","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085\u20137. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571\n                    \n                  .","journal-title":"Circulation"},{"key":"579_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","volume":"19","author":"DY Wang","year":"2017","unstructured":"Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19:21. \n                    https:\/\/doi.org\/10.1007\/s11886-017-0835-0\n                    \n                  .","journal-title":"Curr Cardiol Rep"},{"key":"579_CR32","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","volume":"71","author":"CG Tocchetti","year":"2018","unstructured":"Tocchetti CG, Galdiero MR, Varricchi G. Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology. J Am Coll Cardiol. 2018;71:1765\u20137. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2018.02.038\n                    \n                  .","journal-title":"J Am Coll Cardiol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0579-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T19:23:06Z","timestamp":1562959386000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0579-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,13]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0579-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,13]]},"assertion":[{"value":"13 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marion Ferreira, Eric Pichon, Delphine Carmier, Emilie Bouquet, C\u00e9cile Pageot, Theodora Bejan-Angoulvant, Marion Campana, Emmanuelle Vermes, and Sylvain Marchand-Adam declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}